로딩 중…
지수 로딩 중…
지노믹트리
228760· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩12,030-3.61%
2026-06-19
Price Chart
지노믹트리-2.59%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 299.06B KRW |
| Revenue | 3.83B KRW |
| Net Income | -8.17B KRW |
| Total Assets | 125.97B KRW |
| Net Assets | 123.47B KRW |
| Employees | 79 |
| Value | |
| P/B | 2.42x |
| P/S | 78.18x |
| FCF Yield | -4.32% |
| Profitability | |
| ROE | -6.62% |
| ROA | -6.49% |
| Op. Margin | -277.10% |
| Revenue Growth | 20.58% |
| Financial Health | |
| Debt Ratio | 102.02% |
| Total Debt | 0 KRW |
| FCF | -12.92B KRW |
| Cash | 8.72B KRW |
| Current Ratio | 56.88x |
| Performance | |
| 1Y Return | -2.59% |
| 1M Return | -11.09% |
| From 52W High | -63.87% |
| 1Y MDD | -65.25% |
| Trading | |
| Volume | 89,202 shares |
| Foreign Own. | 2.27% |
| Per Share | |
| EPS | -328 KRW |
| BPS | 5,022 KRW |
Company Info
Genomictree was established in 2000 as a specialized enterprise for cancer auxiliary diagnosis, listed on KONEX, and then transferred its listing to KOSDAQ in 2019. Headquartered in Yuseong-gu, Daejeon, it possesses DNA methylation biomarker discovery and ultra-sensitive detection technology, developing and commercializing body fluid-based non-invasive early cancer diagnosis products. Its flagship product, EarlyTect-C, received Ministry of Food and Drug Safety approval in 2018 and is sold in domestic hospitals and clinics, with technology transfer completed and product approval applications underway in China.